An observational retrospective, multicentre study confirmed the high safety and efficacy of guselkumab in adults having moderate to severe plaque psoriasis. Investigators undertook this study for exploring guselkumab's safety and efficacy at twenty-four weeks to manage psoriasis in routine clinical practice.

Researchers evaluated 343 participants, out of which 249 guselkumab-treated participants were followed for twenty-four weeks. By week twenty-four, the mean (standard deviation) Psoriasis Area and Severity Index (PASI) decreased from 11.1 (7.3) to 1.7 (2.8). Overall, 85.9% of participants had attained a PASI score of four or less and 77.9% had attained a PASI score of two or less.

Regarding relative PASI response, 59.4% of people attained a PASI-90 response and 49% of people attained a PASI-100 response. On multivariate assessment, two factors were noted to decrease the probability of PASI of two or less at twenty-four weeks: (i) Body mass index ≥30 (Odds ratio 0.44), and (ii) Greater previous exposure to biologic therapy (Odds ratio 0.69).

During the study, rare adverse events were noted (9.9%) and resulted in withdrawal from therapy in only nine participants (2.6%) by the end of follow-up period. Compared to relative value, the absolute PASI score seems to be a superior marker of response to therapy in medical care practice, concluded the study authors.